GEN Exclusives

More »

GEN News Highlights

More »
Nov 15, 2006

Los Alamos Analyzes Antibodies Using Lumera Technology

  • Lumera’s Heterodimer Protein Technology (HPT) and ProteomicProcessor™ were successfully used to analyze single chain antibodies from Los Alamos National Laboratory (LANL). “Currently, we are using e-coil tagged, single chain antibodies in a high-throughput flow cytometry-based screening and characterization,” says Peter Pavlik, project leader at Los Alamos. “Having access to Lumera’s high-throughput SPR-based characterization technology that uses the same coil chemistry would increase our ability to characterize antibodies in great detail.”

    The LANL single chain antibodies were engineered to contain the Lumera E-Coil peptide tag. The engineered antibodies were then screened using the Lumera NanoCapture™ K-Coil microarray slide and ProteomicProcessor instrument system.

    “The extraordinary revenue growth rate of therapeutic antibodies is one of the most attractive in the pharmaceutical industry,” points out Ronald Dudek, director of business development at Lumera. “We believe that applied nanotechnology solutions, like those we will offer, will increase the speed and efficiency of pharmaceutical drug discovery.”



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?